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Abstract
Malaria is one the world’s most widespread lethal diseases. Plasmodium falciparum, 
P. vivax, P. ovale, P. malariae and P. knowlesi induce human pathology. These species 
could be differentially diagnosed using the genotyping of cytochrome b, Pfdhfr and 
RNA 18S. The persistence of P. falciparum, the most lethal parasite, is mainly due to 
antimalarial drug resistance. Indeed, a few years after the start of the ambitious malaria 
eradication program in 1960, chloroquine resistance emerged in Asia and spread widely 
in all the endemic areas. It was associated with genotypes in P. falciparum chloroquine 
resistance transporter (CVIET, SVMNT, CVMNT, CVIDT, SVIET and CVMET). The use 
of new drugs such as sulfadoxine-pyrimethamine (SP) leads quickly to SP-resistant 
parasites associated with genotypes on P. falciparum DiHydroFolate reductase (I51-R59-
N108-I164) and P. falciparum DiHydroPteroate synthetase (436-437-580-613). Recently, 
the delay of parasite clearance has been described with artemisinine (the most effica-
cious antimalarial drug). This resistance was associated with the K13 propeller genotype. 
Since malaria species and antimalarial drug resistance markers could be characterized 
using nucleic acid sequences, genotyping is needed for malarial monitoring of species 
distribution and antimalarial drug resistance.
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1. Introduction
Malaria remains a major public health problem. More than 40% of the world’s population 
(3.3 billion) live malarial endemic areas in varying degrees. Despite tremendous efforts in the 
fight, and though this strategy or plan resulted in significantly decreasing the burden in the 
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last 20 years, Malaria still is persistent in nearly 91 countries (Figure 1). In 2016, the overall 
incidence was 216 million cases among these and 445,000 deaths were recorded [1]. Africa 
continues to account for 90% of malaria burden. African children under 5 years of age are the 
most affected. This infectious disease is due to the invasion of Plasmodium spp. Currently, the 
five species are known to infect and to induce significantly malaria in humans are Plasmodium 
ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium vivax and Plasmodium falciparum.
P. falciparum is the most virulent species as it is responsible for more than 90% of malaria 
deaths [2, 3]. Its specific biology with antigenic variation, sequestration of infected blood cells 
and interactions with host cells leads to severe malaria [4, 5]. Also, it is the most recent human 
infection with limited adaptation in the host [6]. P. knowlesi, which is a specific Asian monkey 
parasite (Macaca genus), was recently transferred to humans, causing high mortality in the 
south of Asia [7–9]. One of its differences from other species is the time of its life cycle which 
is 24 h whereas 40–48 h for other human Plasmodium spp. P. vivax is the most prevalent in 
Asia and South America. Due to the Duffy-negative statue of Black people, it is the rarest in 
Black Africa. However, recent studies reported the presence of P. vivax in Blacks with Duffy-
negative from some countries of central Africa such as Equatorial Guinea, Congo Republic 
and so on [10, 11]. P. malariae is less prevalent in Asia, while it is most common in sub-Saharan 
Africa and southwest Pacific [12]. It often finds minor prevalence compared to P. falciparum. 
This parasite is thought to be a zoonotic infection because is genetically close to P. brasilianum 
which infects monkeys of South America [12, 13]. P. ovale is prevalent in Sub-Saharan Africa, 
South-East Asia, India, Papua New Guinea, Timor and Indonesia [14]. It is the less-prevalent 
human malarial parasite. However, in most places where P. ovale is observed, it is relatively 
uncommon and its prevalence rarely exceeds 5% [12].
Figure 1. Countries endemic for malaria in 2000 and 2016. From WHO [1].
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Decisions concerning malaria treatment depend on the identification of the species caus-
ing the disease. Traditionally, this diagnosis was based on the microscopic detection of 
Plasmodium parasites in Giemsa-stained blood slides. In recent decades, antigen detection 
assays and molecular detection assays were introduced as alternatives to microscopy [15]. 
These approaches were very useful; however, they are not very reliable. Indeed, the morpho-
logical features and life history traits of a parasite species can vary from one host species to 
another [16, 17]. For antigen detection assays are mainly aimed at the identification of P. fal-
ciparum. Indeed [18], only a few assays are able to identify infections caused by other human 
malaria parasites [15, 19]. However, the development of molecular tools for the identifica-
tion of species in diagnosis and genotyping permits a better reading of plasmodial diversity 
circulating among the human population and allows best highlighting the phenomenon of 
resistance of Plasmodium than microscopic tools.
Plasmodium species like several other genera have specific genetic markers such as 18S rRNA, 
ITS, cytochrome b and so on, used in studying speciation. These markers play an important 
role in molecular analysis of genotyping and monitoring antimalarial drug resistance. The 
persistence of malaria burden is partly due to the emerging and widespread nature of the 
antimalarial drug resistance. Indeed, in the 1950s, WHO launched the malaria eradication 
program, with chloroquine and dichloro-diphenyl-trichloroethan (DDT). But in the early 1960s, 
chloroquine resistance emerged [20, 21]. Antimalarial drug resistance is defined as the para-
site’s ability to survive after the absorption of drug doses is greater than patient-tolerated 
doses. This chapter described the methods of genotyping the malaria for species diagnosis 
that helps to monitor drug resistance.
2. Genotyping for Plasmodium spp. diagnosis
The genotyping of Plasmodium spp. infections allows for the characterization of distinct spe-
cies and subpopulations present in hosts. The genotyping techniques presented in the follow-
ing allow for the characterization of different Plasmodium species by sizing the polymerase 
chain reaction (PCR) product of the polymorphic marker gene merozoite surface protein.
2.1. PCR using the specificity of 18S RNA
rRNA is one of the ribosome components. Among rRNA, the 18S rRNA gene is the most fre-
quently cited marker for malaria detection. It is composed of highly conserved regions which 
can be targeted for a qualitative detection of Plasmodium spp. and of variable zones allowing 
species identification. Early in the 1990s, Snounou and colleagues reported high-sensitivity 
methods for the detection of plasmodium species using nested PCR [22]. This method was 
based on the conversion of 18S rRNA among human plasmodium and the specificity of 18S 
rRNA from each parasite. So, the method includes the first PCR with primers named rPLU1/5 
and rPLU3/4 that match with human plasmodium. This step is followed by the amplification 
of the product of primary PCR separately with the four species-specific primer pairs: rFAL1 
and rFAL2, rVIV1 and rVIV2, rMAL1 and rMAL2 and rOVA1 and rOVA2 to identify the 
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species P. falciparum, P. vivax, P. malariae and P. ovale, respectively. The primary PCR with 
rPLU1/5 and rPLU3/4 gives a 1100 bp band in a 2% agarose gel electrophoresis (Figure 2), in 
the presence of Plasmodium.
The nested PCR rFAL1 and rFAL2 generate a 205 bp in presence of the P. falciparum parasite. 
The nested PCR rVIV1 and rVIV2 generate a 120 bp in presence of the P. vivax parasite. The 
nested PCR rMAL1 and rMAL2 generate a 144 bp in presence of the P. malaria parasite. The 
nested PCR rOVA1 and rOVA2 generate an 800 bp in presence of the P. ovale parasite [22, 23].
2.2. RT-PCR NASBA 18S rRNA
Nucleic acid sequence-based amplification (NASBA) is a method in molecular biol-
ogy, which is used to amplify RNA sequences. This novel approach of genotyping, based 
on the amplification of nucleic acid sequence (real-time QT-NASBA), was developed by 
Compton [24]. Immediately after its discovery, the NASBA method was used for the rapid 
diagnosis and quantification of HIV-1 in patients [25]. Some years later, Schooner et al. 
[26] developed a real-time quantitative nucleic acid sequence-based amplification (real 
time QT-NASBA) for the detection of Plasmodium falciparum 18S rRNA with a sensitivity 
of 10–50 parasites/ml [26, 27]. Thus, NASBA method that uses primers and probes were 
selected on the basis of the sequence of the small subunit 18S rRNA gene [26, 28], to char-
acterize or identify the different human Plasmodium species [18]. For NASBA, Schooner 
et al. have defined primers Plas-1F (59-TCAGATACCGTCGTAATCTTA-39) and Plas-2R T7 
(59-AATTCTAATACGACTCACTATAGGGAGAGAACTTTCTCGCTTGCGCGAA-39) which 
were used [26]. The RNAs from P. falciparum, P. malariae, P. vivax and P. ovale are specifics 
Figure 2. Specificity and sensitivity of the PCR detection assay. (a) Nested PCR amplification for the demonstration of 
the specificity of the primers employed. Control genomic DNA from P. falciparum (F), P. vivax (V), P. malariae (M), P. ovale 
(O) and human blood (H); (b) nested PCR assay for the detection of in vitro cultured P. falciparum ring-stage parasites; 
(c) nested PCR amplification using diluted control DNAs; (d) product of amplification of diluted control DNAs, using 
the PCR assay (Source: Snounou et al. [22]).
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and they should all be amplified by the NASBA isolates with these primers. Therefore, detec-
tion is done by capture probe (59-ACCATAAACTATG CCGACTAGG-39) which is bound 
to magnetic beads. Finally, samples are hybridized separately to ruthenium-labeled WT 
(59-CCTTATGAGAAATCAAAGTC 39) and Q (59-AATAACTGCACCAGTGTATA-39) detec-
tion probes, followed by ECL detection in a NucliSens ECL reader [26, 29]. The NASBA 
method is very sensitive and specific. It can be used for the detection, identification and quan-
titative measurement of low parasitaemia of Plasmodium species, that is, the lower detection 
limit of the assay is 100–1000 molecules in vitro RNA for all human malaria parasites.
2.3. PCR sequencing cytochrome b
Cytochrome b (Cyt-b) is one of the respiratory chain systems present in mitochondria. It is 
highly conserved in Plasmodium species. But some of its region shows diversities and species 
specificities. It is also in multiple copies (20–100 copies) in the haploid genome, suggesting 
the increase of sensitivity. So, the alignment of Cyt-b sequences obtained after amplification 
by the nested PCR portion of mitochondrial DNA using couples of primers (Table 1) allows 
distinguishing the Plasmodium species present in the host (Figure 3).
The first round of PCR (PCR
1
) and use of the primers DW2/F and DW4/R produce the frag-
ments of 1253 bp. In the second round of PCR (PCR
2
), primers Cyt-b1F and Cyt-b2R are used 
and this generates PCR fragments of 939 bp [30]. This approach was used more for the charac-
terization of malaria parasites in primates (human and non-human) [31, 32] because it allows 
to identify all species known or unknown circulating in vertebrates [33].
2.4. PCR-RFLP from cytochrome b
Due to the specie specificity and diversity of Cytochrome b, it could be digested with the r 
estriction enzyme Alu I leading to species-specific patterns [34]. In this case, a nested PCR 
is used. Primers Plas 1 (5′-GAGAATTATGGAGTGGATGGTG-3′) and Plas 2 (5′-GTGGTAA 
TTGACATCCWATCC-3′) are used for primary PCR producing an 816 bp fragment, follow-
ing by a nested with Plas 3 and Plas 4 primers. The n-PCR produces a 787 bp fragment. The 
digestion with Alu I gives 159 and 640 bp fragments; 187, 249 and 381 bp fragments; 111, 169, 
187, 249 and 270 bp; and 224 and 584 bp fragments for P. falciparum, P. malariae, P. vivax and 
P. ovale, respectively, on agarose gel electrophoresis (Figure 4).
Table 1. Amplification primers of the cytochrome b gene (Cyt-b). Cyt-b is amplified by nested PCR.
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2.5. PCR-DHFR
Figure 5 shows the equation of transformation of dihydrofolate to tetrahydrofolate. The 
dihdrofolate reductase is one of the important malaria proteins involved in the plasmo-
dium folate synthesis. This gene is coded in chromosome 4 and is highly conserved between 
Figure 4. Illustration of a digestion cytochrome fragment using Alu enzyme.
Figure 3. The tree of relationship of Plasmodium species. This tree was built with a portion of Cyt-b sequences characterized 
among some patients and other Cyt-b sequences from Genbank (accession numbers AB489194, EU880499, GU723548 
and GU723532). The tree was built using maximum likelihood with Cyt-b sequences of 925pb sizes.
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distantly related species, like plasmodium species. Its linker region revealed significantly a 
higher sequence diversity than the relatively conserved enzymatic diversity. Different spe-
cies of Plasmodium are characterized by a unique linker sequence. So, it has been used to iden-
tify human plasmodium species [35]. Nonsynonymous mutations on DHFR are associated 
with pyrimethanime resistance. Using primers ATGGARSAMSTYTSMGABGTWTTYGA 
and AAATATTGRTAYTCTGGRTG for primary PCR gives a 1000 bp fragment. The nested 
PCR species specific with primers shown in Table 2 allow to amplify specifically 160, 177, 
144, 231/237/243 and 134 bp fragments for P. falciparum, P. malariae, P. vivax, P. ovale and 
P. knowlesi.
Figure 5. The equation of the DHF-THF reaction. Dihydrofolate reductase is an enzyme that catalyzes the NADPH-
dependent reduction of dihydrofolate to tetrahydrofolate. This reaction is essential for the de novo synthesis of purines 
and certain amino acids. This enzyme is essential for rapid growth and is the target for the action of the important 
antimalarial drugs pyrimethamine and proguanil.
Primer Species Sequence (5′–3′) Annealing 
(°C)
No. of 
cycles
Product 
(bp)
Pla-DHFR-F
Pla-TS-R
Plasmodium sp. ATGGARSAMSTYTSMGABGTWTTYGA
AAATATTGRTAYTCTGGRTG
50 30 1000
Pla-
DHFR-NF
Pla-TS-R
Plasmodium sp. AAATGYTTYATYATWGGDGG
AAATATTGRTAYTCTGGRTG
55 35 509–587
PF-Lin-F
PF-Lin-R
P. falciparum AAAAGGAGAAGAAAAAAATAA
AAAATAAACAAAATCATC
50 35 160
PM-Lin-F
PM-Lin-R
P. malariae GACCCAAGAATCCCTCCC
CCCATGAAGTTATATTCC
50 35 177
PV-Lin-F
PV-Lin-R
P. vivax CGGGAGCACTGCGGACAGCG
CACGGGCACGCGGCGGGGC
55 35 144
PO-Lin-F
PO-Lin-R
P. ovale GACACACAAAATGATGGGGA
ATTGTCCTTTCCTTGACTCG
55 35 231, 237 
or 243
PK-Lin-F
PK-Lin-R
P. knowlesi CGATGGATATGGATAGTGG
CGCGGGAGAGCATTTCCTC
58 35 134
Table 2. Primer sequences and the PCR condition for detection of Plasmodium spp. that infect humans.
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3. Genotyping for the monitoring of antimalarial drug resistance
3.1. Antimalarial drug resistance
Antimalarial drug resistance is the ability of P. falciparum to survive after absorption of the 
drug at concentrations greater than concentrations tolerated by the patient. Drug resistance 
arises rarely because it is the result of some non-lethal mutations, but it spreads relatively 
quickly. The clinical failure treatment is the lasted event in the long way of changes in para-
sites genes. Antimalarial drug resistance markers are genes associated with antimalarial drug 
resistance. Among them, the most characterized are Pfcrt (P. falciparum chloroquine resistance 
transporter), Pfmdr1 (P. falciparum multidrug resistance 1), Pfdhfr (P. falciparum dihydrofolate 
reductase), Pfdhps (P. falciparum dihydropteroate synthase), Pfmrp (P. falciparum multidrug resis-
tance protein), Pfatpase 6 (P. falciparum atpase 6) and PfK13 (P. falciparum kelch 13).
3.2. The genotyping of markers associated with antimalarial drug resistance
3.2.1. P. falciparum chloroquine resistance transporter (Pfcrt)
Pfcrt is an ATP binding cassette (ABC) protein, able to fixe and hydrolyze ATP. The general 
structure of the ABC transporter contains cytosolic nucleotide binding domains (NBDs), a 
nucleotide hydrolysis site and transmembrane segments. These transporters extrude effec-
tive drugs from the digestive vacuole and function as an efflux pump leading to the decrease 
of intracellular accumulation of drugs in the parasite. The genetic cross-experiment between 
chloroquine-sensitive and chloroquine-resistance strains allowed the identification of P. falci-
parum chloroquine-resistance transporter (Pfcrt) in 2000 [20, 36]. It is a 45 kDa protein coding 
in chromosome 7, containing 10 predicted transmembrane domains located on the membrane 
of the digestive vacuole (Figure 6).
Several mutations have been identified in this transporter. The main mutation T76 allows for 
the abolition of accumulation of the drug chloroquine in the digestive vacuole. The association 
of mutations in codons 72, 73, 74, 75 and 76 defined different haplotypes. These haplotypes 
show a spatio-temporal specificity. CVMNK is the wild-type haplotype that is found in chlo-
roquine-sensitive parasites. In Africa, the most prevalent chloroquine-resistance haplotype is 
the CVIET. It was also found with less prevalence in South America and in Southeast of Asia. 
Another Pfcrt resistance haplotype, named South American haplotype, is the SVMNT. That 
is rarely found in Africa and Asia, has relatively little fitness cost and was associated with the 
emergence of amodiaquine resistance too [37, 38]. The other main Pfcrt-resistance haplotypes 
were CVMNT, CVMET, SVIET and CVIDT. CVMNT is most prevalent in South America 
and in Asia but rarely found in Africa [39, 40]. CVMET is the rarest haplotype found in Asia 
whereas SVIET is the South American haplotype. CVIDT is the specific haplotype from 
Asia. Haplotypes CVIET and SVMNT were also associated with the plasmodial resistance 
against amodiaquine and lumefantrine [41]. In our recent study from Gabon and Congo we 
found new haplotypes. But the involvement of these in antimalarial resistance is needed yet 
(unpublished yet). The withdrawal of chloroquine has led to the decrease of the T76 genotype. 
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Furthermore, recent data showed that the use of artemisinine-based combination therapies, 
mainly artemether-lumefantrine, selected the wild-type K76 genotype. Other polymorphisms 
in Pfcrt were described including A144F, I194T, A220S, Q271E and N326S [40].
For the genotype haplotype 72–76 of Pfcrt, PCR sequencing and PCR-RFLP are used. That is 
based on nested PCR with several primers (Table 3). The RFLP pattern indicates a specific 
genotype for each codon.
3.2.2. Plasmodium falciparum multidrug resistance 1 (Pfmdr1)
P. falciparum multidrug resistance 1 is a homologous of the bacterial multidrug resistance 1 
protein. It is one of the main antimalarial drug resistance markers. Like Pfcrt, Pfmdr1 is also 
an ABC transporter, located in the membrane of a digestive vacuole, coded in chromosome 5 
by the 4758 bp gene. Its structure shows two homologous parts containing six transmembrane 
domains plus a nucleotide binding domain (Figure 7).
Some isolates exhibit multicopies of Pfmdr1. Polymorphisms in codons 82, 184, 1034, 1042 
and 1246 (N86Y, Y184F, S1034C, N1042D and D1246Y) were associated with antimalarial 
resistance against mefloquine, lumefantrine, artemether, halofantrine, quinine and chloro-
quine [36, 42]. Copy number and polymorphisms of the pfmdr1 gene have been investigated as 
molecular markers of mefloquine resistance. With the treatment of artemether-lumefantrine, 
a selection of N86 genotype was reported [43]. That was confirmed in areas where this ACT 
was implemented [44]. In same way, it was shown that ACT led to the selection of haplotypes 
NFD, NYD in codons 86, 184, 1246.
Figure 6. The predicted structure and representative haplotypes of P. falciparum chloroquine-resistance transporter. 
PfCRT is predicted to have 10 transmembrane domains, with its N and C terminals located on the cytoplasmic side 
of the digestive vacuole membrane. Mutations identified in the Pfcrt cDNA sequences from CQR lines (black circles), 
the crucial K76T mutation common to all CQR strains (red) and the S163R mutation identified in the amantadine- and 
halofantrine-resistant parasites (yellow circle) are indicated (this figure was pulled in [40]).
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Figure 7. Genetic polymorphisms in P. falciparum multidrug resistance-1. PfMDR1 has two homologous halves, each 
with six predicted transmembrane domains and a nucleotide-binding pocket. The nucleotide-binding domains (NBD1 
and NBD2; orange boxes) are each formed by large cytoplasmic domains. Polymorphic amino acids found in the K1 
allele (N86Y) and the 7G8 allele (Y184F, S1034C, N1042D and D1246Y) are indicated. The D1246Y mutation is located in 
the predicted NBD2 (this figure was pulled, from Ref. [40]).
To the genotype Pfmdr1, followed primers and restriction enzymes are used for PCR-RFLP 
or for PCR followed by sequencing gene. Digestion of PCR products gives fragments of 126 
and 165 bp for mutant 86Y whereas wild type N86 is not digested by restriction enzyme Afl 
III. In codon 1246, wild-type D1246 is digested by restriction enzyme Bgl II, giving fragments 
of 113 and 90 bp, whereas the mutant is not digested (Table 4). For codon 184, the genotype is 
assessed using the PCR followed by sequencing.
Genes, codons Primer 
names
Primers T°C Restriction 
enzyme
Sizes 
(bp)*
Pfcrt, C72S CRT72MS TTTATATTTTAAGTATTATTTATTTAAGTGGA 55 Mbo I 55 + 38
76-D2 CAAAACTATAGTTACCAATTTTG
Pfcrt, M74I CRT745MS TAAGTATTATTTATTTAAGTGTATGTGTCAT 55 Nla III 53 + 31
76-D2 CAAAACTATAGTTACCAATTTTG
Pfcrt, N75M CRT745MS TAAGTATTATTTATTTAAGTGTATGTGTCAT 50 BspHI 53 + 31
76-D2 CAAAACTATAGTTACCAATTTTG
Pfcrt, 76 Pfcrt-76A GCGCGCGCATGGCTCACGTTTAGGTGGAG 55 Apo I 136 + 56
Pfcrt-76B GGGCCCGGCGGATGTTACAAAACTATAGTTACC
Sizes* indicate the sizes of fragments generated after restriction enzyme digestions. T°C= hybridization temperature 
during PCR program.
Table 3. Sequences of primer sets and restriction enzymes used to characterize polymorphisms.
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3.2.3. Plasmodium falciparum dihydrofolate reductase (PfDHFR)
P. falciparum dihydrofolate reductase is mainly involved in the synthesis of the thymidine 
base. This enzyme is the target of pyrimethamine which blocked the synthesis of DNA and 
lead to the death of the parasite. After implementation of this drug, isolates with resistance 
against it were described. This parasite carried the mutations in the Pfdhfr gene. Among these, 
the mutation of serine to asparagine in codon 108 is the main resistance mutation. Additional 
mutations in codons 16, 51, 59 and 164 contribute to the increase of the resistance level of the 
parasite against pyrimethamine. The double mutant 108N + 51I and 108N + 59R increased the 
IC50 of parasites from 2 to 16 times, compared to the simple mutant N108 [45, 46]. In this way 
the triple mutant 51I + 59R + 108N or 59R + 108N + 164R shows the highest resistance level 
compared to the double mutant. Quadruple mutants exhibit a higher level of resistance com-
pared to the triple mutant [47]. In Africa, the AIRNI haplotype is the most prevalent. PCR-
RFLP was developed to genotype Pfdhr codons associated with pyrimethamine resistance. 
For these, primers and restriction enzyme are contained in Table 5..
Genes, 
Codons
Primer names Primers T°C Restriction 
enzyme
Sizes (bp)*
Pfmdr1, 
N86Y
mdr86D1 TTTACCGTTTAAATGTTTACCTGC 45 Afl III 126 + 165
mdr86D2 CCATCTTGATAAAAAACACTTCTT
Pfmdr1, 
D1246Y
mdr1246D1 AATGTAAATGAATTTTCAAACC 45 Bgl II 113 + 90
mdr1246D2 CATCTTCTCTTCCAAATTTGATA
Sizes* indicate the sizes of fragments generated after restriction enzyme digestions. T°C = hybridization temperature 
during PCR program.
Table 4. Sequences of primer sets and restriction enzymes used to characterize Pfmdr1 polymorphisms.
Table 5. Primer sets and RFLP conditions to genotypes PfDHFR and PfDHPS.
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3.2.4. Plasmodium falciparum dihydropteroate synthase (PfDHPS)
P. falciparum dihydropteroate synthase (Pfdhps) is one of the enzymes involved in the line of 
thymidine synthesis. It transforms pteridine to dihydropteroate in the presence of pABA. It is 
coded by the gene located in chromosome 8 of P. falciparum. The implementation of sulfadox-
ine to treat malaria led to P. falciparum isolates’ resistance against this drug. Genotype analysis 
reported the association of Pfdhps mutations with sulfadoxine resistance [48]. So, mutations 
S436A, A437G, K540E, G581A and A613S were reported [49]. The mutation A437G increased 
the IC
50
 of isolates by five times [50]. Isolates with triple mutations S436A + A437G + K540E 
and S436A + A437G + A613S showed the level of sulfadoxine resistance around 9–24 times 
higher than the single mutant.
Triple mutant I51R59N108 in Pfdhfr and double mutants G437E540 and G437S581S in Pfdhps 
increase the risk of failure when treated with sulfadoxine-pyrimethamine [51]. The drug resis-
tance against sulfadoxine and pyrimethamine could be monitored by genotyping Pfdhfr and 
Pfdhps according to the PCR-RFLP conditions shown in Table 5.
3.2.5. Plasmodium falciparum ATPase 6 (PfATPASE6)
The sarcoplasmic/endoplasmic reticulum Ca2+-ATPase, ortholog of P. falciparum (PfSERCA or 
PfATPase6), is an active Ca2+ protein transporter. This is a part of P-type ATPases enzymes that 
transport ions across biological membranes with the energy provided by the ATP hydrolysis. 
Several P-type ATPases, that were reported in P. falciparum and Pfserca, correspond to type 6. The 
gene coding this protein is located in chromosome 1 and contains 3687 bp. The protein allows the 
trafficking of calcium though the sarcoplasmic-endoplasmic membrane. Several polymorphisms 
such as S769N, Y243H, K431E, G110A, A2694T or E623A were reported in PfATPase 6.
PfATPase 6 has been associated with antimalarial drug resistance [52]. The most important 
paper on this protein was the report of its involvement in artemisinin resistance [53]. But, 
the role of PfATPase 6 in artemisinin resistance was strongly disputed. S769 N was associ-
ated with artemether resistance in French Guinea [53]. However, several articles investigating 
PfATAPase 6 in artemisinin drug resistance failed to confirm this point [54–56]. Genotyping 
using PCR followed by sequencing is usually used to monitor antimalarial drug resistance. 
Primers used are previously described by Tahar et al. [57].
3.2.5.1. P. falciparum multidrug resistance protein (PfMRP)
P. falciparum multidrug resistance protein is another marker of antimalarial drug resistance. It 
belongs to the C subfamily of ABC transporters containing two NBDs, two membrane-span-
ning domains and six transmembrane domains. Pfmrp can transport glutathione, glucuro-
nate, as well as glucuronide and sulfate-conjugated compounds that increased susceptibility 
to several antimalarial drugs like chloroquine, quinine or artemisinin [58]. Pfmrp1 and Pfmrp2 
are expressed in the plasma membrane in all asexual stages of the parasite. Their expres-
sion is upregulated by mefloquine and chloroquine. Pfmrp1 is a 215 kDa protein coding on 
chromosome 1. Mutations on codons H191Y and S437A were associated with quinoline resis-
tance [59]. But no association was found between these polymorphisms and resistance against 
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pyronaridine [60]. The hypothetic mechanism of involving of Pfmrp on antimalarial drug 
resistance is the pump efflux mechanism associated with the extrusion of glutathione. The 
genotyping of Pfmrp 1 and Pfmrp2 is achieved using PCR followed by sequencing. The prim-
ers used for amplification and sequencing are pfmrp-501F 5′-TTT CAA AGT ATT CAG TGG 
GT-3′ and pfmrp-1409R 5’-GGC ATA ATA ATT GAT GTA AA-3′.
3.2.5.2. P. falciparum Kelch 13 (PfK13)
Chinese populations used Artemisia annua to treat malaria for a long time. Over the years, arte-
misinin was extracted from this plant. That is a sesquiterpene lactone. Now, artemisinin is one of 
the best antimalarial drugs. So, WHO recommends the use of this drug in association with other 
antimalarial drugs, artemisinin combination therapy (ACT) for the treatment of uncomplicated 
malaria. Since the 1990s, the use of artemisinin was highly intensified in Asia. Consequently, the 
delay of P. falciparum clearance was reported after treatment with artemisinin which translates 
to artemisinin resistance [56]. These slow clearance rates are associated with enhanced survival 
rates of ring-stage parasites briefly exposed in vitro to dihydroartemisinin. Recently, a large-
scale study identified molecular markers of this resistance: polymorphisms on propeller kelch 
13 (K13) [61]. That is a region on chromosome 13 (Figure 8) [62].
Several investigations on K13 genotyping reported that mutations M476I, Y493H, R539T, 
I543T, P553L and C580Y conferred a greater artemisinin resistance [63]. Other mutations 
F446I and A578S were described in PfK13. A578S, widespread in Africa, is not associated with 
artemisinin resistance. These genotypes are investigated by PCR sequencing.
Figure 8. P. falciparum kelch13 (K13) protein. The parasite K13 protein consists of plasmodium-specific sequences, a BTB-
POZ domain and six kelch domains that are predicted to form a six-blade propeller. In the structural model, the original 
M476I mutation discovered by Ariey et al. [61] and six other mutations associated with artemisinin resistance (all details 
of this figure was pulled of Fairhurst and Dondrop [62]) are shown.
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4. Conclusions
Due to the nucleotide specificities of each Plasmodium species and the molecular changes asso-
ciated with antimalarial drug resistance, genotyping is used for Plasmodium species diagnosis 
and monitoring antimalarial drug resistance. This genotyping could be achieved by specific 
PCR, PCR-RFLP, PCR-sequencing or RT-PCR of some molecular markers.
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